NASDAQ:RYTM

Rhythm Pharmaceuticals Stock Forecast, Price & News

$19.02

-1.00 (-5.00 %)

(As of 07/26/2021 12:00 AM ET)

Add

Compare

Today's Range

$18.82

▼

$19.89

50-Day Range

$18.52

▼

$22.54

52-Week Range

$18.00

▼

$43.26

Volume262,307 shs

Average Volume284,614 shs

Market Capitalization$954.99 million

P/E RatioN/A

Dividend YieldN/A

Beta1.45

30 days | 90 days | 365 days | Advanced Chart

Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and AlstrÃ¶m syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

BRIEF-Rhythm Announces European Commission Authorization Of Imcivree
July 23, 2021 | msn.com

Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for the Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency
July 23, 2021 | finance.yahoo.com

Rhythm Pharma's Imcivree Gets European Approval For Obesity, Control of Hunger Associated With Genetic Mutations
July 23, 2021 | finance.yahoo.com

Rhythm Pharmaceuticals, Inc. : Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel
July 23, 2021 | markets.businessinsider.com

Rhythm Launches Electricity Plans Backed By 100% Solar Power Generated in Texas
July 22, 2021 | markets.businessinsider.com

Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE (setmelanotide) in Israel
July 22, 2021 | finanznachrichten.de

Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel
July 22, 2021 | finance.yahoo.com

Worldwide Cardiac Monitoring & Cardiac Rhythm Management Industry to 2025 - Measures to Reduce Infections Caused due to CIEDs Presents Opportunities
July 21, 2021 | benzinga.com

Global Cardiac Rhythm Management Devices Market Research Report 2021 - ResearchAndMarkets.com
July 20, 2021 | finance.yahoo.com

Do Insiders Own Lots Of Shares In Rhythm Biosciences Limited (ASX:RHY)?
July 19, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RYTM
Previous Symbol
CUSIPN/A
CIK1649904
Webwww.rhythmtx.com
Phone857-264-4280
Employees90
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.76 per share
Price / Book5.06

Profitability

EPS (Most Recent Fiscal Year)($3.04)
Net Income$-134,000,000.00
Net MarginsN/A
Return on Equity-23.12%
Return on Assets-21.00%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares50,210,000
Market Cap$954.99 million
Next Earnings Date8/2/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.54 out of 5 stars

Medical Sector

1099th out of 4,434 stocks

Pharmaceutical Preparations Industry

535th out of 1,734 stocks

3.4 Analyst's Opinion

Consensus Rating
Rhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.67, Rhythm Pharmaceuticals has a forecasted upside of 166.4% from its current price of $19.02.
Amount of Analyst Coverage
Rhythm Pharmaceuticals has received no research coverage in the past 90 days.

2.6 Community Rank

Outperform Votes
Rhythm Pharmaceuticals has received 243 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Rhythm Pharmaceuticals has received 231 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Rhythm Pharmaceuticals has received 51.27% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote “Outperform” if you believe RYTM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Rhythm Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rhythm Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rhythm Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.49% of the stock of Rhythm Pharmaceuticals is held by insiders.
Percentage Held by Institutions
94.64% of the stock of Rhythm Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Rhythm Pharmaceuticals are expected to decrease in the coming year, from ($2.01) to ($2.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rhythm Pharmaceuticals is -13.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rhythm Pharmaceuticals is -13.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rhythm Pharmaceuticals has a P/B Ratio of 5.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

Is Rhythm Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Rhythm Pharmaceuticals stock.
View analyst ratings for Rhythm Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Rhythm Pharmaceuticals?

Wall Street analysts have given Rhythm Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rhythm Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Rhythm Pharmaceuticals' next earnings date?

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Rhythm Pharmaceuticals.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its earnings results on Sunday, May, 2nd. The company reported ($1.16) EPS for the quarter, missing the Zacks' consensus estimate of $0.30 by $1.46. The firm earned $0.04 million during the quarter, compared to the consensus estimate of $99 million.
View Rhythm Pharmaceuticals' earnings history.

How has Rhythm Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RYTM shares have increased by 26.8% and is now trading at $19.02.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for RYTM?

6 brokers have issued 12 month price objectives for Rhythm Pharmaceuticals' shares. Their forecasts range from $33.00 to $67.00. On average, they expect Rhythm Pharmaceuticals' share price to reach $50.67 in the next year. This suggests a possible upside of 166.4% from the stock's current price.
View analysts' price targets for Rhythm Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the following people:

Dr. David P. Meeker, Chairman, Pres & CEO (Age 67, Pay $836.08k)
Mr. Hunter C. Smith, CFO & Treasurer (Age 52, Pay $692.84k)
Dr. Murray W. Stewart M.D., Chief Medical Officer (Age 60, Pay $744.89k)
Ms. Jennifer L. Chien, Exec. VP & Head of North America (Age 46, Pay $194.95k)
Mr. William T. Roberts, Chief Accounting Officer (Age 42)
Mr. Joseph Shulman, Sr. VP of Technical Operations
Mr. David Connolly, Head of Investor Relations & Corp. Communications
Mr. Jim Flaherty, Sr. VP & Gen. Counsel
Mr. Satej Bhandarkar, Sr. VP of Program Management, Strategy & Corp. Devel.
Mr. Yann Mazabraud, Exec. VP & Head of International (Age 48)

What is 's approval rating as Rhythm Pharmaceuticals' CEO?

1 employees have rated Rhythm Pharmaceuticals CEO on Glassdoor.com. has an approval rating of 100% among Rhythm Pharmaceuticals' employees. This puts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Rhythm Pharmaceuticals' key competitors?

Some companies that are related to Rhythm Pharmaceuticals include Arena Pharmaceuticals (ARNA), Alkermes (ALKS), Galapagos (GLPG), Lyell Immunopharma (LYEL), Emergent BioSolutions (EBS), ACADIA Pharmaceuticals (ACAD), Karuna Therapeutics (KRTX), Cerevel Therapeutics (CERE), Agios Pharmaceuticals (AGIO), Turning Point Therapeutics (TPTX), Nektar Therapeutics (NKTR), Intra-Cellular Therapies (ITCI), Rocket Pharmaceuticals (RCKT), PTC Therapeutics (PTCT) and Dicerna Pharmaceuticals (DRNA).
View all of RYTM's competitors.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $19.02.

How much money does Rhythm Pharmaceuticals make?

Rhythm Pharmaceuticals has a market capitalization of $954.99 million. The company earns $-134,000,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does Rhythm Pharmaceuticals have?

Rhythm Pharmaceuticals employs 90 workers across the globe.

What is Rhythm Pharmaceuticals' official website?

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

Where are Rhythm Pharmaceuticals' headquarters?

Rhythm Pharmaceuticals is headquartered at 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here